Drugs / allogeneic tumor cell vaccine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00162513 | Dec 2006 → ? | chronic myeloid leukemia | Hadassah Medical Organization | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00814892 | Jan → Dec 2009 | prostate cancer | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT00002773 | May 1996 → Apr 2004 | pancreatic adenocarcinoma | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00002475 | Apr 1991 → Dec 2007 | breast cancer, colorectal cancer, kidney cancer, lung cancer +2 | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic tumor cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00162513 ↗ |
| Action | Deplete | “Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells.” NCT00002475 ↗ |
| Modality | Vaccine | “allogeneic active-specific intralymphatic immunotherapy with a vaccine containing interferon alfa or interferon gamma-treated tumor cells” NCT00002475 ↗ |
| Route | Other | “patients receive viable tumor cells via dorsal pedal lymphatic cannulation” NCT00002773 ↗ |